Sjogren, Per, Bragée, Bjorn, Britton, Sven · Clinical therapeutics · 2024 · DOI
This study tested a treatment called subcutaneous immunoglobulin (a protein that helps the immune system) in 17 ME/CFS patients whose symptoms seemed to be triggered by infections. After 5 weeks of treatment, patients reported significant improvements in their symptoms, quality of life, and ability to work, with no serious side effects. One patient reported their ME/CFS symptoms disappeared completely.
This research provides preliminary evidence that immunoglobulin therapy may benefit a specific subset of ME/CFS patients—those with infection-related symptomatology—which could represent a step toward precision medicine approaches in this understudied disease. The findings support further investigation into immune-based treatments and suggest that not all ME/CFS patients are homogeneous in their treatment response.
This case series does not prove that immunoglobulin is an effective ME/CFS treatment for all patients; it only suggests potential benefit in patients with infection-driven symptoms. Without a control group or blinding, improvements could be partially attributed to placebo effect or natural disease fluctuation. The short 5-week timeframe does not establish whether benefits persist long-term.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Sjogren, Per, Bragée, Bjorn, & Britton, Sven (2024). Successful Subcutaneous Immunoglobulin Therapy in a Case Series of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.. Clinical therapeutics. https://doi.org/10.1016/j.clinthera.2024.05.010
BibTeX
@article{mecfsatlas-sjogren-2024-successful-subcutaneous,
author = {Sjogren, Per and Bragée, Bjorn and Britton, Sven},
title = {Successful Subcutaneous Immunoglobulin Therapy in a Case Series of Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.},
journal = {Clinical therapeutics},
year = {2024},
doi = {10.1016/j.clinthera.2024.05.010},
note = {PubMed: 38910072},
url = {https://www.mecfsatlas.com/evidence/sjogren-2024-successful-subcutaneous},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-30. https://www.mecfsatlas.com/evidence/sjogren-2024-successful-subcutaneous
Contribute
Private, reviewed by a human. Not a public comment thread.